Abstract
Hundreds of somatic ERBB4 (HER4) mutations have been described in cancer tissues with very limited information available about their functional significance. Understanding the activity of ERBB4 mutations is needed to assess the relevance of targeting ERBB4 in human cancers with matched therapies, such as neratinib. Neratinib is an irreversible pan-ERBB tyrosine kinase inhibitor that potently inhibits ERBB4, and is currently approved for early stage and metastatic HER2+ breast cancers, and is under clinical evaluation for EGFR-, ERBB2-, and ERBB4-mutant cancers, including in the SUMMIT clinical trial (NCT01953926).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
